GoldMining Commences Pre-Feasibility Study and Begins Infill Drilling with Three Drills at the São Jorge Project, Brazil

GoldMining Inc. (TSX: GOLD, NYSE American: GLDG) has started a pre-feasibility study and a 6,000-metre infill drilling program at its São Jorge Gold Project in Brazil. The goal is to upgrade mineral resources and gather data for future metallurgical and geotechnical studies. The company expects to complete the study by the first half of 2028. The project previously had a preliminary economic assessment with an after-tax NPV5% of US$532 million and an IRR of 42.4%.

Original reporting
Published Oct 28, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$GLDG
Neutral
medium confidence
Mentioned
$GLDG
Relevance
6/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$GLDGNeutralLow
01

Why it matters

The announcement signals progress toward a PFS expected in early 2028, potentially increasing resource confidence and attracting capital.

02

Market read

A development update for a gold exploration company; may modestly influence the stock and sector sentiment.

03

What to watch

Financing availability, permitting timelines, and gold price volatility could affect project economics.

Relevance 6/10Novelty 6/10Timing: today

Background

GoldMining Inc. (TSX:GOLD, NYSE American:GLDG) is a junior gold explorer with projects across the Americas. The São Jorge project in Brazil is at the pre‑feasibility stage.

Company-level read

Ticker impact

$GLDGNeutralMedium confidence
Context

GoldMining Inc. announced the start of a pre‑feasibility study and a 6,000‑metre infill drilling program at its 100% owned São Jorge gold project in Brazil.

Expected impact

potential modest upside as investors price in de‑risking progress

Evidence & confidence

No immediate financial numbers are disclosed; the news is a development update that may gradually lift sentiment.

Market effects

May improve outlook for junior gold miners and the broader exploration sector.

Positive signal for Brazil's mining investment climate.

Limited; primarily relevant to commodity‑focused investors.

Counterpoint

If drilling results are disappointing, the stock could face pressure despite the announced de‑risking effort.

Key entities

  • GoldMining Inc.

    Junior gold explorer reporting the drilling program.

  • Alastair Still

    CEO of GoldMining Inc., quoted in the release.

Related articles

$GLDGMed

GoldMining ups São Jorge value in new report

GoldMining Inc. filed a technical report for its São Jorge gold project in Brazil, including the previously announced PEA. Using a 5% discount rate and gold at $3,500/oz, it estimates after-tax NPV of $532m, IRR 42.4%, and at $4,400/oz NPV $836.8m with 2.4-year payback. Mine life is 10.6 years, producing ~51,250 oz/year, peak 57,200 oz, with AISC $1,464/oz.

$GLDGMed

GoldMining Files PEA Technical Report for its La Mina Project, Colombia - Highlighting $1.0 Billion After-Tax NPV and 32% IRR

GoldMining Inc. said it filed an NI 43-101 technical report for its La Mina gold-copper project in Antioquia, Colombia, including an updated 2026 PEA (effective April 22, 2026). The study estimates an after-tax NPV5% of $1.0 billion and IRR of 32.2% (initial payback ~2.7 years), rising to $1.8 billion NPV5% and 49.1% IRR at spot prices. Initial capex is $523 million; average first-five-year output is 152.4 koz AuEq.

$AVRMedAI 8/10

Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients

Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.